As on Wednesday, Chromocell Therapeutics Corp. (AMEX: CHRO) got off with the flyer as it spiked 22.22% to $0.89, before settling in for the price of $0.73 at the close. Taking a more long-term approach, CHRO posted a 52-week range of $0.52-$6.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -33.33%. This publicly-traded company’s shares outstanding now amounts to $5.88 million, simultaneously with a float of $1.54 million. The organization now has a market capitalization sitting at $5.14 million. At the time of writing, stock’s 50-day Moving Average stood at $0.7997.
Chromocell Therapeutics Corp. (CHRO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Chromocell Therapeutics Corp.’s current insider ownership accounts for 73.29%, in contrast to 9.34% institutional ownership. According to the most recent insider trade that took place on Sep 12 ’24, this organization’s Director bought 10,400 shares at the rate of 0.94, making the entire transaction reach 9,825 in total value, affecting insider ownership by 91,565. Preceding that transaction, on Sep 13 ’24, Company’s CEO, Pres., CFO, Treas & Secty bought 3,500 for 0.97, making the whole transaction’s value amount to 3,395. This particular insider is now the holder of 547,710 in total.
Chromocell Therapeutics Corp. (AMEX: CHRO) Trading Performance Indicators
Let’s observe the current performance indicators for Chromocell Therapeutics Corp. (CHRO). It’s Quick Ratio in the last reported quarter now stands at 0.93. The Stock has managed to achieve an average true range (ATR) of 0.13.
In the same vein, CHRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.68, a figure that is expected to reach -0.23 in the next quarter.
Technical Analysis of Chromocell Therapeutics Corp. (CHRO)
Through scrutinizing the latest numbers posted by the [Chromocell Therapeutics Corp., CHRO], it can be observed that its last 5-days Average volume of 0.28 million was better the volume of 47086.0, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 81.07% While, its Average True Range was 0.1260.
Raw Stochastic average of Chromocell Therapeutics Corp. (CHRO) in the period of the previous 100 days is set at 30.16%, which indicates a major fall in contrast to 77.29% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 189.01% that was higher than 137.49% volatility it exhibited in the past 100-days period.
